- Home
- CBUS vs QNCX Comparison
CBUS vs QNCX Comparison
Compare CBUS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBUS
- QNCX
- Stock Information
- Founded
- CBUS 2010
- QNCX 2012
- Country
- CBUS United States
- QNCX United States
- Employees
- CBUS N/A
- QNCX N/A
- Industry
- CBUS Agricultural Chemicals
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBUS Industrials
- QNCX Health Care
- Exchange
- CBUS Nasdaq
- QNCX Nasdaq
- Market Cap
- CBUS 72.0M
- QNCX 85.9M
- IPO Year
- CBUS 2017
- QNCX 2019
- Fundamental
- Price
- CBUS $1.38
- QNCX $1.61
- Analyst Decision
- CBUS Strong Buy
- QNCX Strong Buy
- Analyst Count
- CBUS 3
- QNCX 6
- Target Price
- CBUS $22.00
- QNCX $8.00
- AVG Volume (30 Days)
- CBUS 197.4K
- QNCX 137.7K
- Earning Date
- CBUS 11-06-2025
- QNCX 11-12-2025
- Dividend Yield
- CBUS N/A
- QNCX N/A
- EPS Growth
- CBUS N/A
- QNCX N/A
- EPS
- CBUS N/A
- QNCX N/A
- Revenue
- CBUS $4,846,000.00
- QNCX N/A
- Revenue This Year
- CBUS $17.67
- QNCX N/A
- Revenue Next Year
- CBUS $63.43
- QNCX N/A
- P/E Ratio
- CBUS N/A
- QNCX N/A
- Revenue Growth
- CBUS 63.66
- QNCX N/A
- 52 Week Low
- CBUS $1.20
- QNCX $0.69
- 52 Week High
- CBUS $6.10
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- CBUS 48.79
- QNCX 49.14
- Support Level
- CBUS $1.32
- QNCX $1.56
- Resistance Level
- CBUS $1.41
- QNCX $1.67
- Average True Range (ATR)
- CBUS 0.08
- QNCX 0.07
- MACD
- CBUS 0.01
- QNCX 0.00
- Stochastic Oscillator
- CBUS 52.31
- QNCX 69.70
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.